Study S002112

Effects of 12 Weeks of Endurance Exercise Training Alone or in Combination With Glucagon Like Peptide 1 Receptor Agonist (GLP-1 RA) Treatment on Insulin Secretory Capacity in Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04383197
Acronym: EXISECRET
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: UNKNOWN
Enrollment: 30
Start: 2019-12-10
Primary completion: 2021-08
Lead sponsor: University of Copenhagen
Conditions: Type 2 Diabetes
Interventions: BEHAVIORAL:Endurance exercise training; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Insulin secretion [Change from baseline insulin secretion after Exercise intervention(12 weeks).]
Insulin secretion [Change from baseline insulin secretion after 3 months of therapeutic semaglutide treatment]
Insulin secretion [Change from baseline insulin secretion after 3 months of combined exercise and therapeutic semaglutide treatment]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020754	Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes. Ingersen A, The Journal of clinical endocrinology and metabolism	2023	Randomized trial	PMID 37265222 DOI	cites ClinicalTrials.gov:NCT04383197; registry reference DERIVED:37265222